Journal
CLINICS IN CHEST MEDICINE
Volume 35, Issue 1, Pages 157-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2013.11.001
Keywords
COPD; Exacerbations; Respiratory viral infections; Bacterial infections
Categories
Funding
- Novartis
- Johnson and Johnson
- Takeda
- Chiesi
- MRC [G0800570] Funding Source: UKRI
- Medical Research Council [G0800570] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0510-10270, NF-SI-0513-10077, RP-PG-0109-10056] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [RP-PG-0109-10056] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
Exacerbations are important events for patients with chronic obstructive pulmonary disease (CORD) and key outcomes in COPD studies and trials. Exacerbations have an impact on health status and contribute to disease progression, and exacerbation prevention is a key goal of therapy in CORD. A majority of CORD exacerbations are triggered by respiratory viral infections and/or bacterial infections. Several pharmacologic therapies can prevent CORD exacerbations and reduce hospital admissions. Nonpharmacologic interventions for exacerbation prevention include pulmonary rehabilitation, long-term oxygen therapy, and home noninvasive ventilator support. Improved management of acute exacerbations also prolongs the time to the next exacerbation event.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available